

SB0069S02

inserted text shows text that was not in SB0069S02 but was inserted into SB0069S06

1

Medication Amendments
2025 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Evan J. Vickers
House Sponsor: Steve Eliason

General Description:

Highlighted Provisions:

- defines $\{\text{terms}\}$ a term;

- ~~{ acquire a 340B drug; or }~~

- ~~{ participate in the 340B drug discount program; }~~

- ▶ permits the Public Employees' Benefit and Insurance Program to adjust its business practices to mitigate any resulting financial impacts{~~;~~and} .

- ▶ ~~{ requires the commissioner of insurance to designate a third party entity to: }~~

- ~~{ receive certain deidentified claim information; }~~

- ~~{ confirm whether a 340B entity participates in the drug discount program; and }~~

SB0069S02 compared with SB0069S06

- {~~report the claim information to a pharmaceutical manufacturer.~~}

Money Appropriated in this Bill:

None

Other Special Clauses:

None

ENACTS:

31A-46-311 , Utah Code Annotated 1953 , Utah Code Annotated 1953

~~{31A-46-312 , Utah Code Annotated 1953 , Utah Code Annotated 1953}~~

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **1** is enacted to read:

31A-46-311. Prohibited actions with respect to the 340B drug discount program.

- (1) As used in this section, "manufacturer" means a pharmaceutical manufacturer, including an agent or affiliate of a pharmaceutical manufacturer.
- (2) A manufacturer may not:
- (a) directly or indirectly restrict or prohibit:
- (i) a pharmacy from contracting with a 340B entity, including by denying the pharmacy access to a drug that is manufactured by the manufacturer;
- (ii) a 340B entity from contracting with a pharmacy, including by denying the 340B entity access to a drug that is manufactured by the manufacturer;
- (iii) the acquisition, dispensing, or delivery of a 340B drug to any location authorized by a 340B entity to receive the drug, unless prohibited by federal law; or
- (iv) a 340B entity from receiving 340B drug discount program pricing for a 340B drug, including by imposing a time limitation on a 340B entity to replenish or submit a claim for a 340B drug;
- (b) directly or indirectly:
- (i) require a 340B entity to purchase a 340B drug from a supplier if the manufacturer would otherwise permit the 340B entity to purchase a drug that is not a 340B drug from the supplier; or
- (ii) require a 340B entity to submit any claim data, utilization data, or information about a 340B entity's contracts with a third-party as a condition for allowing the acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity, unless the data or information sharing is required by federal law;
- or

SB0069S02 compared with SB0069S06

(c) interfere with:

(i) a contract between a pharmacy and a 340B entity; or

(ii) the ability of a pharmacy and a 340B entity to enter into a contract.

(3) The Public Employees' Benefit and Insurance Program created in Section 49-20-103 may adjust the program's business practices to mitigate any financial impacts resulting from this section.

(4) Nothing in this section is to be construed to conflict with federal law.

Section 2. Section 2 is enacted to read:

31A-46-312. Designated entity -- Claim information sharing and use -- 340B entity public reporting.

(1) As used in this section:

(a) "Board of pharmacy" means the Utah State Board of Pharmacy created in Section 58-17B-201.

(b) "Claim information" means information related to a claim for a 340B drug that is:

(i) dispensed by a contract pharmacy; and

(ii) manufactured by a single manufacturer.

(c) "Contract pharmacy" means a pharmacy contracting with an entity participating in the 340B drug discount program to dispense drugs purchased through the 340B drug discount program.

(d) "Designated entity" means a third party entity that is designated as described in Subsection (2).

(e) "Participating 340B entity" means a 340B entity that is a hospital described in 42 U.S.C. Sec. 256b(a)(4)(L).

(2)

(a) The commissioner, in collaboration with the board of pharmacy, shall designate one third party entity to receive claim information as described in Subsection (3).

(b) In making the designation described in Subsection (2)(a), the commissioner shall ensure that the third party entity:

(i) is capable of carrying out the requirements of this section;

(ii)

(A) is not owned or controlled by a pharmaceutical manufacturer; and

(B) does not otherwise have a contractual or other relationship with a pharmaceutical manufacturer that would create a conflict of interest; and

(iii) in carrying out the provisions of this section, will use:

(A) technology that complies with privacy and security requirements under state and federal law; and

SB0069S02 compared with SB0069S06

(B) reasonable and necessary terms.

(c) If the commissioner is unable to designate a third party entity that meets the requirements of Subsection (2)(b), a participating 340B entity is not required to post as described in Subsection (6).

(3) A participating 340B entity shall:

(a) provide to the designated entity the following claim information:

(i) prescription number;

(ii) prescribed date;

(iii) fill date;

(iv) national drug code;

(v) quantity;

(vi) pharmacy identification; and

(vii) 340B covered entity identification;

(b) ensure the claim information provided is deidentified in accordance with federal law; and

(c) provide the claim information in accordance with the rules described in Subsection (7).

(4) Upon request, the designated entity:

(a) shall inform a pharmaceutical manufacturer whether a 340B entity is a participating 340B entity that provides claim information for any 340B drug; and

(b) may provide to a pharmaceutical manufacturer claim information for a 340B drug manufactured by the pharmaceutical manufacturer that the designated entity received under Subsection (3).

(5)

(a) The designated entity or a pharmaceutical manufacturer may only use claim information received under this section to identify a rebate for an insurer or a third party administrator that is ineligible for payment under the pharmaceutical manufacturers policy.

(b) The designated entity or a pharmaceutical manufacturer may not use claim information received under this section to:

(i) establish restrictions or limitations on a participating 340B entity's ability to purchase a 340B drug, including by establishing:

(A) allocations on purchasing based on the number of claims for which the participating 340B entity provides claim information; or

(B) time limits for a participating 340B entity to replenish or replace inventory of a 340B drug;

(ii) recoup from a participating 340B entity a discount for a 340B drug;

SB0069S02 compared with SB0069S06

- (iii) discriminate against, lower the reimbursement for, or impose any separate condition on a participating 340B entity; or
- (iv) take any other action that is not expressly authorized under this part.
- (6) A participating 340B entity shall post on the participating 340B entity's publicly available website:
- (a) the name of the participating 340B entity;
- (b) a copy of the participating 340B entity's annual 340B program recertification;
- (c) if the participating 340B entity is required to conduct a community health needs assessment under Section 501(r)(3)(A), Internal Revenue Code, a copy of the participating 340B entity's community health needs assessment;
- (d) a statement that the participating 340B entity is in compliance with the 340B drug discount program; and
- (e) a description of the impact of the 340B drug discount program on the patients and community served by the participating 340B entity.
- (7) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the commissioner, in collaboration with the board of pharmacy, shall make rules that establish the frequency in which a participating 340B entity shall provide claim information to the designated entity.

Section 2. **Effective date.**

Effective Date.

This bill takes effect on May 7, 2025.

3-4-25 3:13 PM